Moore P A, Crout R J, Jackson D L, Schneider L G, Graves R W, Bakos L
Department of Dental Public Health, University of Pittsburgh, School of Dental Medicine, Pennsylvania 15261, USA.
J Clin Pharmacol. 1998 Jun;38(6):554-60. doi: 10.1002/j.1552-4604.1998.tb05794.x.
Tramadol hydrochloride is a novel, centrally acting analgesic with two complementary mechanisms of action: opioid and aminergic. Relative to codeine, tramadol has similar analgesic properties but may have fewer constipating, euphoric, and respiratory depressant effects. A two-center randomized double-blind controlled clinical trial was performed to assess the analgesic efficacy and reported side effects of tramadol 100 mg, tramadol 50 mg, codeine 60 mg, aspirin (ASA) 650 mg with codeine 60 mg, and placebo. Using a third molar extraction pain model, 200 healthy subjects were enrolled in a 6-hour evaluation after a single dose of drug. Of the 200 patients enrolled, seven provided incomplete efficacy data or discontinued prematurely and one was lost to follow-up. Using standard measures of analgesia, including total pain relief score (TOTPAR), maximum pain relief score (MaxPAR), sum of pain intensity difference scores (SPID), peak pain intensity difference (Peak PID), remedication, and global evaluations, all active treatments were found to be numerically superior to placebo. ASA/codeine was found to be statistically superior to placebo for all measures of efficacy. Tramadol 100 mg was statistically superior to placebo for TOTPAR, SPID, and time of remedication, whereas tramadol 50 mg was statistically superior to placebo onlyfor remedication time. Codeine was not found to be statistically superior to placebo for any efficacy measure. A greater TOTPAR response compared with all other active measures was seen for ASA/codeine during the first 3 hours of study. The 6-hour TOTPAR scores for the tramadol groups and ASA/ codeine group were not significantly different. Gastrointestinal side effects (nausea, dysphagia, vomiting) were reported more frequently with tramadol 100 mg, ASA/ codeine, and codeine 60 mg than with placebo.
盐酸曲马多是一种新型的中枢性镇痛药,具有两种互补的作用机制:阿片样物质和胺能机制。与可待因相比,曲马多具有相似的镇痛特性,但便秘、欣快感和呼吸抑制作用可能较少。进行了一项双中心随机双盲对照临床试验,以评估100毫克曲马多、50毫克曲马多、60毫克可待因、650毫克阿司匹林(ASA)与60毫克可待因以及安慰剂的镇痛效果和报告的副作用。使用第三磨牙拔除疼痛模型,200名健康受试者在单剂量用药后进行了6小时的评估。在纳入的200名患者中,7名提供的疗效数据不完整或过早停药,1名失访。使用包括总疼痛缓解评分(TOTPAR)、最大疼痛缓解评分(MaxPAR)、疼痛强度差异评分总和(SPID)、峰值疼痛强度差异(Peak PID)、再次用药和总体评估等标准镇痛指标,发现所有活性治疗在数值上均优于安慰剂。发现ASA/可待因在所有疗效指标上均在统计学上优于安慰剂。100毫克曲马多在TOTPAR、SPID和再次用药时间方面在统计学上优于安慰剂,而50毫克曲马多仅在再次用药时间方面在统计学上优于安慰剂。在任何疗效指标上,未发现可待因在统计学上优于安慰剂。在研究的前3小时内,与所有其他活性治疗相比,ASA/可待因的TOTPAR反应更大。曲马多组和ASA/可待因组的6小时TOTPAR评分无显著差异。与安慰剂相比,100毫克曲马多、ASA/可待因和60毫克可待因报告的胃肠道副作用(恶心、吞咽困难、呕吐)更频繁。